phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
Published 1 year ago • 110 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
3:21
a phase i trial of hu8f4, an anti-pr1/hla-a2 monoclonal antibody, in r/r myeloid malignancies
-
2:42
results from a phase i study of cc-98633 in r/r myeloma
-
4:58
findings of a phase i study of anitocabtagene autoleucel for the treatment of r/r myeloma
-
2:41
a phase i/ii study of afm13 in combination with cord blood-derived nk cells in patients with r/r hl
-
12:17
updated iv and sc results from a phase i dose escalation study of forimtamig with rrmm patients
-
1:28
diagnostic criteria for castleman disease & the development of a novel symptom score
-
2:47
a study comparing br to ibrutinib in the frontline treatment of waldenström's macroglobulinemia
-
0:33
ivim microscopy
-
3:13
how to optimally sequence agents in the expanding treatment armamentarium of multiple myeloma
-
1:59
novel targets and therapeutics being explored in waldenström's macroglobulinemia
-
0:47
the potential of early intervention for high-risk patients with waldenström's macroglobulinemia
-
3:37
primary analysis of the randomized phase ii trial of vrd and elotuzumab for nd hrmm: swog-1211
-
0:48
what is expansion microscopy?
-
0:18
study cell growth over time | holomonitor®
-
0:37
running lifetime studies with fibro prisma - elearning | cytiva
-
0:25
meta-imu, systematic review, step 12: summary of findings